非布司他适合什么人用呢？

Who is Febuxostat suitable for? Febuxostat (febuxostat, feburic) is a xanthine oxidase (XO) inhibitor indicated for the long-term treatment of hyperuricemia with gout symptoms. This product is not recommended for the treatment of asymptomatic hyperuricemia.

The production of uric acid in the body is related to purine metabolism. In the final step of purine metabolism, hypoxanthine generates xanthine under the action of xanthine oxidoreductase (XOR), and then further generates uric acid. Inhibiting the activity of this enzyme can effectively reduce the production of uric acid. Febuxostat acts highly selectively on this oxidase, reducing uric acid synthesis in the body and lowering uric acid concentration, thereby effectively treating gout.

Febuxostat is an oral drug. Normally, the initial recommended dose for patients is 40 mg/day. If the symptoms are severe, it can be adjusted to 80 mg/day. If the serum uric acid level is still higher than 6 mg/dL after taking 40 mg/day for 2 weeks, the dose can be increased to 80 mg/day.

In the early stage of taking the drug, the serum uric acid concentration drops rapidly, which can promote the mobilization of uric acid deposited in the tissue, so symptoms similar to a gout attack may occur. In this case, nonsteroidal anti-inflammatory drugs or colchicine can be used for preventive administration. In addition, some patients need to be monitored for symptoms related to myocardial infarction and liver damage during febuxostat treatment.

The safety and efficacy of febuxostat (febuxostat, feburic) in gout were evaluated based on a multi-center, double-blind, randomized phase II clinical study. A total of 136 men and 17 women with gout were randomized to receive placebo or febuxostat (40, 80, or 120 mg/day). After 4 weeks, the test found that the serum uric acid concentration of patients in each dose group of febuxostat was significantly lower than before treatment. According to the dose, each group decreased by an average of 37%, 44% and 59% respectively, while the patients in the placebo group only decreased by 2%. Febuxostat has shown positive effects in the treatment of gout patients.